Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022

(marketscreener.com) KNOXVILLE, TN, Nov. 10, 2022 -- Provectus today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer immunotherapy PV-10, an intratumoral formulation of Provectus’ small molecule rose bengal sodium , and immune checkpoint inhibitor KEYTRUDA® for the treatment of...https://www.marketscreener.com/quote/stock/PROVECTUS-BIOPHARMACEUTIC-120787445/news/Provectus-Biopharmaceuticals-Announces-Acceptance-of-Small-Molecule-Cancer-Immunotherapy-PV-10-Stag-42270363/?utm_medium=RSS&utm_content=20221110